Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 15:229:13-21.
doi: 10.1016/j.amjcard.2024.08.005. Epub 2024 Aug 14.

External Validation of the Recalibrated HEART Score for Evaluation of Possible Acute Coronary Syndrome

Affiliations

External Validation of the Recalibrated HEART Score for Evaluation of Possible Acute Coronary Syndrome

Edward Hyun Suh et al. Am J Cardiol. .

Abstract

A single high-sensitivity troponin-T (hs-TnT) measurement may be sufficient to risk-stratify emergency department (ED) patients with possible acute coronary syndrome (ACS) using the recalibrated History, Electrocardiogram, Age, Risk Factors, Troponin (rHEART) score. We sought to validate this approach in a multiethnic population of United States patients and investigate gender-specific differences in performance. We conducted a secondary analysis of a prospective cohort study of adult ED patients with possible ACS at a single, urban, academic hospital. We investigated the diagnostic performance of rHEART for the incidence of type-1 acute myocardial infarction (AMI) and other major adverse cardiac events (MACE) at 30 days, using both single (19 ng/L) and gender-specific (14 ng/L for women, 22 ng/L for men) 99th percentile hs-TnT thresholds. The 821 patients included were 54% women, 57% Hispanic, and 26% Black. Overall, 4.6% of patients had MACE, including 2.4% with AMI. Single-threshold rHEART ≤3 had a sensitivity of 94.4% (95% confidence interval 81% to 99%) and negative predictive values of 99.3% (98% to 100%) for MACE; gender-specific thresholds performed nearly identically. Sensitivity and negative predictive values for AMI were 90.0% (67% to 98%) and 99.3% (97% to 100%). Excluding patients presenting <3 hours from symptom onset improved sensitivity for MACE and AMI to 97.0% (84% to 100%) and 94.1% (71% to 100%). Logistic regression demonstrated odds of MACE increased with higher rHEART scores at a similar rate for men and women. In conclusion, a single initial hs-TnT and rHEART score can be used to risk-stratify male and female ED patients with possible ACS, especially when drawn >3 hours after symptom onset.

Keywords: acute coronary syndrome; high-sensitivity cardiac troponin.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Edward Suh reports a relationship with Roche Diagnostics that includes: funding grants. Bryn Mumma reports a relationship with Roche Diagnostics that includes: consulting or advisory. Marc Probst reports a relationship with Roche Diagnostics that includes: non-financial support. Andrew Einstein reports a relationship with Ionetix that includes: speaking and lecture fees. Andrew Einstein reports a relationship with WL Gore and Associates that includes: consulting or advisory and funding grants. Andrew Einstein reports a relationship with Canon Medical Systems Corporation that includes: consulting or advisory and funding grants. Lauren Ranard reports a relationship with Boston Scientific Corporation that includes: funding grants. Andrew Einstein reports a relationship with Attralus, Inc. that includes: funding grants. Andrew Einstein reports a relationship with BridgeBio that includes: funding grants. Andrew Einstein reports a relationship with GE Healthcare that includes: funding grants. Andrew Einstein reports a relationship with Intellia Therapeutics Inc that includes: funding grants. Andrew Einstein reports a relationship with Ionis Pharmaceuticals Inc that includes: funding grants. Andrew Einstein reports a relationship with Neovasc Inc that includes: funding grants. Andrew Einstein reports a relationship with Roche Medical Systems that includes: funding grants. Andrew Einstein reports a relationship with Pfizer that includes: funding grants. Co-author, AJE, has recieved authorship fees from Wolters Kluwer Healthcare - UpToDate. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

LinkOut - more resources